911300-51-1

Basic information

• Product Name: Benzofuran, 2,3-dihydro-6-nitro-
• Synonyms: Benzofuran, 2,3-dihydro-6-nitro-;6-Nitro-2,3-dihydrobenzofuran
• CAS NO: 911300-51-1
• Molecular Formula: C8H7NO3
• Molecular Weight: 0
• Mol File: 911300-51-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzofuran, 2,3-dihydro-6-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzofuran, 2,3-dihydro-6-nitro-(911300-51-1)
• EPA Substance Registry System: Benzofuran, 2,3-dihydro-6-nitro-(911300-51-1)

Safety Data

• Hazardous Substances Data: 911300-51-1(Hazardous Substances Data)

Upstream product

• 84594-78-5 6-nitro-2,3-dihydro-1-benzofuran-5-ylamine 
• 17403-47-3 5-nitro-2,3-dihydro-1-benzofuran 
• 496-16-2 2.3-dihydrobenzofuran 
• 7169-34-8 3-oxo-2,3-dihydrobenzo[b]furan 
• 81926-25-2 5-acetamido-2,3-dihydrobenzo<1,2-b>furan 
• 42933-43-7 2,3-dihydro-1-benzofuran-5-amine 

Downstream Products

• 57786-34-2 6-amino-2,3-dihydrobenzofuran 

Relevant articles and documents

Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain

In order to discover a novel type of analgesic, we investigated dual activity ligands with TRPV1 antagonism and mu-opioid receptor affinity with the goal of eliciting synergistic analgesia while avoiding the side effects associated with single targeting.

Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template

In an effort to design inhibitors of human glutaminyl cyclase (QC), we have synthesized a library of N-aryl N-(5-methyl-1H-imidazol-1-yl)propyl thioureas and investigated the contribution of the aryl region of these compounds to their structure-activity relationships as cyclase inhibitors. Our design was guided by the proposed binding mode of the preferred substrate for the cyclase. In this series, compound 52 was identified as the most potent QC inhibitor with an IC50 value of 58 nM, which was two-fold more potent than the previously reported lead 2. Compound 52 is a most promising candidate for future evaluation to monitor its ability to reduce the formation of pGlu-Aβ and Aβ plaques in cells and transgenic animals.

4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, R6, B, D, E, G, Q, x and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1—R4 A, B, D, E, and G are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins

A series of novel tricyclic triazine-di-N-oxides (TTOs) related to tirapazamine have been designed and prepared. A wide range of structural arrangements with cycloalkyl, oxygen-, and nitrogen-containing saturated rings fused to the triazine core, coupled with various side chains linked to either hemisphere, resulted in TTO analogues that displayed hypoxia-selective cytotoxicity in vitro. Optimal rates of hypoxic metabolism and tissue diffusion coefficients were achieved with fused cycloalkyl rings in combination with both the 3-aminoalkyl or 3-alkyl substituents linked to weakly basic soluble amines. The selection was further refined using pharmacokinetic/pharmacodynamic model predictions of the in vivo hypoxic potency (AUCreq) and selectivity (HCD) with 12 TTO analogues predicted to be active in vivo, subject to the achievement of adequate plasma pharmacokinetics.

TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS

The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.